Gacos-B (01167) rose more than 5%. The stock closed up more than 16% yesterday. As of press release, it rose 5.07% to HK$2.28, with a turnover of HK$2,031,800.
The Zhitong Finance App learned that Gacos-B (01167) rose more than 5%, and the stock closed up more than 16% yesterday. As of press release, it rose 5.07% to HK$2.28, with a turnover of HK$2,031,800.
According to the news, a new drug marketing application (NDA) for the KRAS G12c inhibitor Glecirasib (JAB-21822) independently developed by Gacos Pharmaceuticals has been officially submitted to the National Drug Administration (NMPA) Drug Evaluation Center (CDE) for second-line treatment of advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutations.
According to a previous research report by Tianfeng Securities, Glace (JAB-21822) is about to be listed, and the efficacy and safety performance is impressive. According to data from the Phase II registered clinical trial of glecirasib, the confirmed objective remission rate (ORR) was 47.9% (56/117) among patients with single-agent second-line non-small cell lung cancer, including 4 patients who achieved complete remission (CR), 36 patients had tumors shrunk by more than 50%, and the disease control rate was 86.3%.